Because IL-17A signaling was accepted as a crucial link for the transition from NAFLD to HCC 41, we further performed an anti-IL-17A treatment in a NASH-HCC transition model established by DEN injection followed by HFMCD/HFD feeding in FGF21KO mice (Figure S7). Here, IL17A is linked to metabolic dysfunction-associated steatotic liver disease.